OCI-AML2(人急性髓系白血?。?/h1>
CBP60527
                       
                         詢  價(jià)
                        
                        
                索取STR
                        
                    產(chǎn)品描述
                    產(chǎn)品數(shù)據(jù)庫(kù)
                    
                | I. General information | |
| Synonyms: | OCI-AML2 | 
| Background: | established from the peripheral blood of a 65-year-old man with acute myeloid leukemia (AML FAB M4) in 1986 at diagnosis; cells were described in the literature to express the retinoic acid receptor gene; cell line carries the DNMT3A R635W mutation | 
| Species: | human (Homo sapiens) | 
| Tissue: | N/A | 
| Disease: | acute myeloid leukemia | 
| Gender: | N/A | 
| Morphology: | single, round to oval cells in suspension; | 
| Growth Mode: | N/A | 
| Doubling Time: | about 30-50 hours | 
| DNA Profile: | N/A Our Cell Line Authentication Service  | 
		
| Culture Medium: | 
				 80% MEM α (GIBCO 12561-056 ) + 20% FBS OCI-AML2完全培養(yǎng)基,# CBP60527M  | 
		
| Cryopreservation medium: | 90%FBS+10%DMSO | 
| Mycoplasma: | negative in DAPI, microbiological culture, RNA hybridization assays | 
| Immunology: | CD3 -, CD4 +, CD13 +, CD14 -, CD15 +, CD19 -, CD33 +, CD34 -, CD68 +, HLA-DR (+); image | 
| Fingerprint: | multiplex PCR of minisatellite markers revealed a unique DNA profile | 
| Species: | confirmed as human with IEF of MDH, NP | 
| Cytogenetics: | human hyperdiploid karyotype with 3.8% polyploidy - 48(43-49)<2n>XY, +6, +8, der(1)inv(1)(p36q31)t(1;6) (q13;p12), der(2)t(2;17)(p23;q24.1)del(2)(q14.2q36), der(3)t(1;3)(p36;p25), ins(3;2)(q21;q14.2q36), t(5;8)(q11.2;q24), der(6)t(1;6)(q31;p12)t(3;6) (q26;q24), inv(12)(p13.3q13.2), t(13;14)(q32/33;q24.2), der(17)t(2;17)(p23;q24.1) - sideline with +der(5) - carries apparent variant translocations involving several ANLL breakpoints: 1p36, 3q21, 3q26 (megakaryocytic abnormalities), 12p13, 17q24 (FAB-M4) | 
| Virus | ELISA: reverse transcriptase negative; PCR: EBV -, HBV -, HCV -, HIV-1 -, HIV-2 -, HTLV-I/II -, MLV -, SMRV - | 
| Comments: | For more information, please contact us (4008-750-250). |